Supplemental Table 2

|  |  |
| --- | --- |
|   | **Kinase Inhibition** |
|  | **Brivanib** | **JNJ-42756943**  |
| **Kinase** | **IC50 (nM)** | **+/- SEM** | **Ratio FGFR/KDR** | **IC50 (nM)** | **+/- SEM** | **Ratio FGFR/KDR** |
| FGFR1 | 35.9 | 2.1 | 4.0 | 1.2 | 0.4 | 0.03 |
| FGFR2 | 43.7 | 4.0 | 4.9 | 2.5 | 0.9 | 0.07 |
| FGFR3 | 104.0 | 7.3 | 11.7 | 3.0 | 0.5 | 0.08 |
| FGFR4 | 332.0 | 25.6 | 37.2 | 5.7 | 0.8 | 0.15 |
| VGFR2 | 8.9 | 0.5 | 1.0 | 36.8 | 7.1 | 1.00 |
|  |  |  |  |  |  |  |
|   | **BaF3 Inhibition** |
|  | **Brivanib** | **JNJ-42756943**  |
| **Kinase** | **IC50 (nM)** | **+/- SEM** | **Ratio FGFR/KDR** | **IC50 (nM)** | **+/- SEM** | **Ratio FGFR/KDR** |
| FGFR1 | 7760 | 518.0 | 5.0 | 22.1 | 0.81 | 0.019 |
| FGFR3 | 7940 | 358.0 | 5.1 | 13.2 | 0.47 | 0.011 |
| FGFR4 | >10000 | NA | >6.5 | 25 | 0.3 | 0.022 |
| VGFR2 | 1550 | 103.0 | 1.0 | 1160 | 30.7 | 1.000 |